MedTrace Logo

A Study of ZW191 in Participants With Solid Tumors

NCT06555744 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-05-07

No results posted yet for this study

Summary

The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.

Conditions

Interventions

DRUG

ZW191

Administered intravenously

Sponsors & Collaborators

  • Zymeworks BC Inc.

    lead INDUSTRY

Principal Investigators

  • Maggie Weinstein, MD, PhD, MPH · Zymeworks BC Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2026-12-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Japan
  • Singapore
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555744 on ClinicalTrials.gov